• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Climb Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    5/14/25 7:05:09 AM ET
    $CLYM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CLYM alert in real time by email
    8-K
    0001768446false00017684462025-05-142025-05-14

     

     

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

    FORM 8-K

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): May 14, 2025

    CLIMB BIO, INC.

    (Exact name of Registrant as Specified in Its Charter)

    Delaware

    001-40708

    83-2273741

    (State or Other Jurisdiction

    of Incorporation)

    (Commission File Number)

    (IRS Employer

    Identification No.)

     

     

     

    20 William Street

    Suite 145

    Wellesley Hills, MA

    02481

    (Address of Principal Executive Offices)

    (Zip Code)

    Registrant’s Telephone Number, Including Area Code: (866) 857-2596

    Not Applicable

    (Former Name or Former Address, if Changed Since Last Report)

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading

    Symbol(s)

     

    Name of each exchange on which registered

     

    Common Stock, par value $0.0001 per share

     

    CLYM

     

    The Nasdaq Stock Market LLC

     (The Nasdaq Global Market)

     

     


     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     


     

    Item 2.02. Results of Operations and Financial Condition.

    On May 14, 2025, Climb Bio, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2025. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein.

     

    The information in this Item 2.02, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended, whether filed before or after the date hereof and regardless of any general incorporation language in such filing.

    Item 9.01. Financial Statements and Exhibits.

    (d) Exhibits.

     

    Exhibit

    Number

    Description

    99.1

    Press release of Climb Bio, Inc., dated May 14, 2025

     104

    Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

     

     

     

    1


     

    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Climb Bio, Inc.

    Date: May 14, 2025

    By:

    /s/ Aoife Brennan

    Aoife Brennan, M.B., Ch.B.

    President and Chief Executive Officer

     

     

    2


    Get the next $CLYM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CLYM

    DatePrice TargetRatingAnalyst
    2/13/2026$23.00Overweight
    Piper Sandler
    10/16/2025Outperform
    William Blair
    10/13/2025$9.00Buy
    H.C. Wainwright
    8/15/2025$9.00Outperform
    Robert W. Baird
    6/6/2025$10.00Outperform
    Oppenheimer
    5/22/2025$7.00Buy
    BTIG Research
    12/2/2024$10.00Outperform
    Leerink Partners
    More analyst ratings

    $CLYM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Piper Sandler initiated coverage on Climb Bio with a new price target

    Piper Sandler initiated coverage of Climb Bio with a rating of Overweight and set a new price target of $23.00

    2/13/26 8:31:53 AM ET
    $CLYM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    William Blair initiated coverage on Climb Bio

    William Blair initiated coverage of Climb Bio with a rating of Outperform

    10/16/25 8:22:17 AM ET
    $CLYM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on Climb Bio with a new price target

    H.C. Wainwright initiated coverage of Climb Bio with a rating of Buy and set a new price target of $9.00

    10/13/25 8:52:19 AM ET
    $CLYM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLYM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Ra Capital Management, L.P. bought $24,888 worth of shares (7,111 units at $3.50) (SEC Form 4)

    4 - Climb Bio, Inc. (0001768446) (Issuer)

    1/7/26 4:55:47 PM ET
    $CLYM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Ra Capital Management, L.P. returned 20,440,000 shares to the company and bought $754,737 worth of shares (314,561 units at $2.40) (SEC Form 4)

    4 - Climb Bio, Inc. (0001768446) (Issuer)

    12/15/25 7:55:04 PM ET
    $CLYM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLYM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Climb Bio to Present at Upcoming Investor Conferences

    WELLESLEY HILLS, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced that members of its executive team will participate in the upcoming conferences detailed below. Guggenheim's Emerging Outlook: Biotech SummitFormat: Fireside ChatDate: Thursday, February 12, 2026Time: 3:00 – 3:25 p.m. ET Oppenheimer 36th Annual Healthcare Life Sciences Conference Format: Fireside ChatDate: Wednesday, February 25, 2026Time: 1:20 – 1:50 p.m. ET Leerink Global Healthcare Conference Format: Fireside ChatDate: Monday, March 9, 2026Time: 2:20 – 2:50 p.m. ET The live

    2/5/26 7:00:00 AM ET
    $CLYM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Climb Bio Announces Pipeline Progress and Strategic Priorities for 2026

    First patients dosed in budoprutug PrisMN Phase 2 trial in pMN, with initial data expected second half 2026  Dosing ongoing in budoprutug Phase 1b/2a trial in ITP and Phase 1b trial in SLE; achieved regulatory clearance for SLE IND in China First patients dosed in CLYM116 Phase 1 healthy volunteer study Anticipating a data-rich 2026, with initial readouts from all ongoing budoprutug and CLYM116 studies Strong financial position with cash runway expected into 2028 WELLESLEY HILLS, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced progress upd

    1/8/26 7:00:00 AM ET
    $CLYM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Climb Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    WELLESLEY HILLS, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM), a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced that Climb Bio has granted an inducement equity award to a new employee, pursuant to the Climb Bio's 2025 Inducement Plan, as amended, as an inducement material to the new employee entering into employment with Climb Bio in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement equity award was granted to one new employee on November 24, 2025, and consisted of a non-statutory stock option to purchase up to an aggregate of 120,000 shares of common stock of Climb Bio, which

    11/25/25 7:00:00 AM ET
    $CLYM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLYM
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Climb Bio Inc.

    SCHEDULE 13G - Climb Bio, Inc. (0001768446) (Subject)

    2/17/26 4:09:59 PM ET
    $CLYM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Climb Bio Inc. filed SEC Form 8-K: Regulation FD Disclosure

    8-K - Climb Bio, Inc. (0001768446) (Filer)

    1/8/26 7:07:49 AM ET
    $CLYM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Climb Bio Inc.

    8-K - Climb Bio, Inc. (0001768446) (Filer)

    12/31/25 4:12:49 PM ET
    $CLYM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLYM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Thomas Stephen Basil sold $529,129 worth of shares (100,000 units at $5.29), decreasing direct ownership by 33% to 204,657 units (SEC Form 4)

    4 - Climb Bio, Inc. (0001768446) (Issuer)

    2/17/26 4:05:10 PM ET
    $CLYM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Business Officer Wilson Perrin Megan

    4 - Climb Bio, Inc. (0001768446) (Issuer)

    1/8/26 4:05:13 PM ET
    $CLYM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by President and CEO Brennan Aoife

    4 - Climb Bio, Inc. (0001768446) (Issuer)

    1/8/26 4:05:18 PM ET
    $CLYM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLYM
    Leadership Updates

    Live Leadership Updates

    View All

    Climb Bio Appoints Susan Altschuller, Ph.D., MBA as Chief Financial Officer

    WELLESLEY HILLS, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced that it has strengthened its leadership team with the addition of Susan Altschuller, Ph.D., MBA, as Chief Financial Officer. Susan brings over two decades of strategic and financial leadership experience. "Susan is a seasoned biopharmaceutical leader with a strong track record in financial strategy, capital allocation, and operational execution, and we are delighted to welcome her to our team," said Aoife Brennan, President and CEO of Climb Bio. "Our company is making excellent progress advanci

    10/1/25 7:00:00 AM ET
    $CLYM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Climb Bio Appoints Edgar D. Charles, M.D., MSc as Chief Medical Officer

    Dr. Charles, Accomplished Immunology-Focused Drug Developer, Brings More Than 20 years of Biopharma Leadership, Clinical Development, and Operations Expertise Company Also Hires Cindy J. Driscoll, MBA, Financial Executive with Over Two Decades of Experience Guiding Biotechnology Companies, as Senior Vice President, Finance WELLESLEY HILLS, Mass., June 18, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced the appointments of Edgar D. Charles, M.D., MSc as its Chief Medical Officer (CMO) and Cindy J. Driscoll, MBA as Senior Vice President, Finance. "The expansi

    6/18/25 7:00:00 AM ET
    $CLYM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors

    WELLESLEY HILLS, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM) today announced the appointments of biotech industry veterans Kim Cobleigh Drapkin, CPA, and Bo Cumbo to its Board of Directors. Ms. Drapkin will assume the role of Audit Committee Chair, and Mr. Cumbo will assume the role of Compensation Committee Chair. "We are delighted to welcome Kim and Bo to our Board of Directors at Climb Bio," said Aoife Brennan, President and CEO of Climb Bio. "Kim and Bo each bring three decades of leadership experience in the biotechnology and pharmaceutical industry, offering invaluable perspective as we continue to build the company and advance our pipeline. Their insight

    4/1/25 7:00:00 AM ET
    $ABOS
    $CLYM
    $LENZ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $CLYM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Climb Bio Inc.

    SC 13G/A - Climb Bio, Inc. (0001768446) (Subject)

    11/14/24 9:29:34 AM ET
    $CLYM
    Biotechnology: Pharmaceutical Preparations
    Health Care